Allianz Asset Management GmbH Raises Stock Position in Embecta Corp. $EMBC

Allianz Asset Management GmbH grew its position in shares of Embecta Corp. (NASDAQ:EMBC) by 176.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,755 shares of the company’s stock after purchasing an additional 91,711 shares during the period. Allianz Asset Management GmbH owned approximately 0.25% of Embecta worth $2,028,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of EMBC. Tower Research Capital LLC TRC boosted its position in Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after buying an additional 6,224 shares during the period. CWM LLC raised its stake in shares of Embecta by 16.0% during the second quarter. CWM LLC now owns 8,080 shares of the company’s stock valued at $78,000 after acquiring an additional 1,115 shares during the last quarter. Humankind Investments LLC purchased a new stake in shares of Embecta during the second quarter worth about $111,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Embecta by 7.9% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock worth $145,000 after purchasing an additional 1,093 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in Embecta during the 2nd quarter valued at about $147,000. 93.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EMBC has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 7th. Finally, BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of Embecta in a report on Friday, February 6th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $18.50.

Embecta Stock Performance

Shares of EMBC opened at $10.00 on Friday. Embecta Corp. has a fifty-two week low of $9.20 and a fifty-two week high of $16.75. The firm’s 50-day simple moving average is $11.61 and its two-hundred day simple moving average is $12.92. The stock has a market cap of $592.20 million, a PE ratio of 4.22 and a beta of 1.11.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm had revenue of $261.20 million for the quarter, compared to analysts’ expectations of $258.07 million. During the same period in the previous year, the firm posted $0.65 EPS. The business’s revenue for the quarter was down .3% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Equities research analysts predict that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 6.0%. The ex-dividend date of this dividend is Friday, February 27th. Embecta’s dividend payout ratio is currently 25.32%.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.